WO2010026467A3 - Forme pharmaceutique à libération prolongée de principe actif hautement soluble - Google Patents

Forme pharmaceutique à libération prolongée de principe actif hautement soluble Download PDF

Info

Publication number
WO2010026467A3
WO2010026467A3 PCT/IB2009/006733 IB2009006733W WO2010026467A3 WO 2010026467 A3 WO2010026467 A3 WO 2010026467A3 IB 2009006733 W IB2009006733 W IB 2009006733W WO 2010026467 A3 WO2010026467 A3 WO 2010026467A3
Authority
WO
WIPO (PCT)
Prior art keywords
citicoline
levetiracetam
water soluble
controlled release
dosage form
Prior art date
Application number
PCT/IB2009/006733
Other languages
English (en)
Other versions
WO2010026467A2 (fr
Inventor
Jaya Abraham
Vinodkumar Gupta
Bhavesh Shah
Original Assignee
Torrent Pharmaceuticals Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Torrent Pharmaceuticals Ltd. filed Critical Torrent Pharmaceuticals Ltd.
Publication of WO2010026467A2 publication Critical patent/WO2010026467A2/fr
Publication of WO2010026467A3 publication Critical patent/WO2010026467A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une forme pharmaceutique orale solide à libération prolongée comprenant un principe actif hautement soluble, la forme pharmaceutique étant fabriquée par granulation en une seule opération au moyen d'au moins un régulateur de libération hydrophobe. Cette forme pharmaceutique est en outre enrobée au moyen d'au moins un régulateur de libération hydrophobe. L'invention concerne également le procédé d'élaboration de ladite forme pharmaceutique.
PCT/IB2009/006733 2008-09-04 2009-09-03 Forme pharmaceutique à libération prolongée de principe actif hautement soluble WO2010026467A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1868/MUM/2008 2008-09-04
IN1868MU2008 2008-09-04

Publications (2)

Publication Number Publication Date
WO2010026467A2 WO2010026467A2 (fr) 2010-03-11
WO2010026467A3 true WO2010026467A3 (fr) 2011-06-03

Family

ID=41797589

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2009/006733 WO2010026467A2 (fr) 2008-09-04 2009-09-03 Forme pharmaceutique à libération prolongée de principe actif hautement soluble

Country Status (1)

Country Link
WO (1) WO2010026467A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010089372A1 (fr) 2009-02-09 2010-08-12 Ucb Pharma, S.A. Compositions pharmaceutiques comprenant du brivaracetam
TR200905670A1 (tr) * 2009-07-22 2011-02-21 Sanovel �La� San.Ve T�C.A.�. Uzatılmış salım sağlayan levetirasetam farmasötik bileşimleri
US9333175B2 (en) * 2010-06-16 2016-05-10 Mylan Inc. Controlled release levetiracetam formulations and methods for producing the same
CN102688214B (zh) * 2012-06-15 2013-05-22 孙威 一种左乙拉西坦缓释片制备方法
WO2014025593A1 (fr) * 2012-08-08 2014-02-13 PharmTak, Inc. Lévétiracétam à libération prolongée et procédé de préparation
KR101659983B1 (ko) * 2012-12-31 2016-09-26 주식회사 삼양바이오팜 용융 압출된 방출 제어용 약학 조성물, 및 이를 포함하는 경구용 제제
CN103191079B (zh) * 2013-04-01 2014-03-26 济南利民制药有限责任公司 一种胞磷胆碱钠片及其制备方法
ES2759801T3 (es) * 2015-08-08 2020-05-12 Tiefenbacher Alfred E Gmbh & Co Kg Formulación gastro-resistente que contiene posaconazol

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5185159A (en) * 1983-07-20 1993-02-09 Sanofi Pharmaceutical composition based on valproic acid and a process for preparing it
WO2000028989A1 (fr) * 1998-11-12 2000-05-25 Smithkline Beecham P.L.C. Composition pharmaceutique a liberation modifiee d'un agent de sensibilisation a l'insuline, et d'un autre agent antidiabetique
WO2001022940A1 (fr) * 1999-09-30 2001-04-05 Edward Mendell Co., Inc. Systemes de matrice a liberation prolongee pour medicaments hautement solubles
WO2003007918A1 (fr) * 2001-07-19 2003-01-30 Phoqus Pharmaceuticals Limited Systeme d'administration de medicaments controle par ordre zero
WO2003047529A2 (fr) * 2001-12-04 2003-06-12 Biovail Laboratories Inc. Comprime pharmaceutique de metformine a liberation prolongee
WO2006080029A1 (fr) * 2005-01-27 2006-08-03 Alembic Limited Formulation de lévétiracétam à libération prolongée
WO2007000779A2 (fr) * 2005-06-29 2007-01-04 Panacea Biotec Ltd. Nouvelles compositions pharmaceutiques a liberation prolongee et procedes pour leur preparation
WO2008062446A2 (fr) * 2006-09-14 2008-05-29 Alembic Limited Composition de lévétiracétam à libération prolongée n'impliquant pas d'effets indésirables en présence d'aliments
FR2912056A1 (fr) * 2007-02-05 2008-08-08 Rd Pharmagal Soc Par Actions S Composition a liberation prolongee de levetiracetam et procede de preparation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY113429A (en) 1995-02-28 2002-02-28 Univ Temple Controlled release tablet containing swellable polyethylene oxide
JP4083818B2 (ja) 1997-06-06 2008-04-30 ディポメド，インコーポレイティド 高度可溶性薬物の制御された放出のための胃滞留性の経口薬物投与形
US6337091B1 (en) 1997-10-27 2002-01-08 Temple University - Of The Commonwealth System Of Higher Education Matrix for controlled delivery of highly soluble pharmaceutical agents
CN1203846C (zh) 1998-03-19 2005-06-01 布里斯托尔-迈尔斯斯奎布公司 高溶解性药物的双相控释递送系统和方法
AU2002230830A1 (en) 2000-11-03 2002-05-15 Andrx Labs, Llc Controlled release metformin compositions
CN1628690A (zh) 2003-12-15 2005-06-22 孟繁浩 胞磷胆碱缓控释制剂及其制备方法
ES2403069T3 (es) 2005-02-22 2013-05-13 Sun Pharma Advanced Research Company Ltd Composición oral de liberación controlada que contiene levetiracetam
US20080014271A1 (en) 2006-07-13 2008-01-17 Ucb, S.A. Novel pharmaceutical compositions comprising levetiracetam

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5185159A (en) * 1983-07-20 1993-02-09 Sanofi Pharmaceutical composition based on valproic acid and a process for preparing it
WO2000028989A1 (fr) * 1998-11-12 2000-05-25 Smithkline Beecham P.L.C. Composition pharmaceutique a liberation modifiee d'un agent de sensibilisation a l'insuline, et d'un autre agent antidiabetique
WO2001022940A1 (fr) * 1999-09-30 2001-04-05 Edward Mendell Co., Inc. Systemes de matrice a liberation prolongee pour medicaments hautement solubles
WO2003007918A1 (fr) * 2001-07-19 2003-01-30 Phoqus Pharmaceuticals Limited Systeme d'administration de medicaments controle par ordre zero
WO2003047529A2 (fr) * 2001-12-04 2003-06-12 Biovail Laboratories Inc. Comprime pharmaceutique de metformine a liberation prolongee
WO2006080029A1 (fr) * 2005-01-27 2006-08-03 Alembic Limited Formulation de lévétiracétam à libération prolongée
WO2007000779A2 (fr) * 2005-06-29 2007-01-04 Panacea Biotec Ltd. Nouvelles compositions pharmaceutiques a liberation prolongee et procedes pour leur preparation
WO2008062446A2 (fr) * 2006-09-14 2008-05-29 Alembic Limited Composition de lévétiracétam à libération prolongée n'impliquant pas d'effets indésirables en présence d'aliments
FR2912056A1 (fr) * 2007-02-05 2008-08-08 Rd Pharmagal Soc Par Actions S Composition a liberation prolongee de levetiracetam et procede de preparation

Also Published As

Publication number Publication date
WO2010026467A2 (fr) 2010-03-11

Similar Documents

Publication Publication Date Title
WO2010026467A3 (fr) Forme pharmaceutique à libération prolongée de principe actif hautement soluble
WO2006011159A3 (fr) Composition pharmaceutique stabilisee contenant du sodium de rabeprazole presentant une biodisponibilite amelioree
IL195269A0 (en) Pharmaceutical formulations for the sustained release of active ingredient(s), as well as their applications, especially therapeutic
WO2009047802A3 (fr) Nouvelle formulation bioadhésive à libération modifiée d'acide 5-aminosalicylique ou de ses sels et de ses métabolites destinée au traitement du colon
WO2006082523A3 (fr) Compositions pharmaceutiques de metformine
WO2011076749A3 (fr) Forme solide de dosage pharmaceutique
EP2103214A4 (fr) Agent de traitement de sols ou de graines comprenant un composé quinoléine ou un sel de celui-ci en tant que substance active, ou procédé pour lutter contre une maladie de plante l'utilisant
WO2010015567A3 (fr) Formulations à libération contrôlée à l'aide de polymères intelligents
WO2007097770A8 (fr) Comprimés de succinate de métoprolol er et méthodes pour leur préparation
WO2010111640A3 (fr) Compositions antigrippales et méthodes associées
WO2004082615A3 (fr) Procede de preparation de comprimes a liberation prolongee
JO2973B1 (en) Fumarate salt for (alpha-beta-R) -6-bromo-alpha-[2- (methylamino) ethyl-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinoline ethanol
WO2009066315A3 (fr) Compositions à libération prolongée de trimétazidine et procédé de préparation
WO2007090661A3 (fr) Combinaison de substances actives
WO2009004082A3 (fr) Compositions pharmaceutiques anticonvulsives
WO2008136392A1 (fr) Préparation pour une administration orale
EP2142549A4 (fr) Dérivés d'adénosine, procédé pour la synthèse de ces derniers, et compositions pharmaceutiques pour la prévention et le traitement de maladies inflammatoires contenant lesdits dérivés en tant qu'ingrédients actifs
WO2008129501A3 (fr) Compositions pharmaceutiques de duloxetine
UA96622C2 (ru) Твердые лекарственные формы, которые содержат алискирен, изготовленные способом сухого гранулирования
WO2011009714A3 (fr) Dérivés de sel de benzoquinolizinium comme agents anti-cancéreux
WO2007098967A3 (fr) Composés ciblant les récepteurs sigma
WO2009084041A3 (fr) Compositions pharmaceutiques de dexibuprofène
WO2008034912A3 (fr) Procédé de synthèse du clopidogrel et nouvelles formes de sels pharmaceutiquement acceptables de celui-ci
WO2009049648A3 (fr) Composition pharmaceutique améliorée contenant un agent antiviral et procédé de préparation de celle-ci
WO2010137040A3 (fr) Nouvelles compositions pharmaceutiques de ranolazine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09771407

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09771407

Country of ref document: EP

Kind code of ref document: A2